mitral valvular disease, MVD
Conditions
Interventions
A:mitral valve diseases type A
B:mitral valve diseases type B
C:mitral valve diseases type C
D:mitral valve diseases type C
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The study group consisted of 32 MVDs patients scheduled for mitral valve replacement surgery.
Exclusion criteria
Exclusion criteria: angiotensin receptor blockers within 1 month, existence of any other valvular stenosis or regurgitation other than mild, recent infection (within 1 month), previous cardiac surgery, hypertension, or any medical condition (eg. Coronary heart disease, Diabetes, Hyperthyroidism) that, in the opinion of the investigators, could render the patient inappropriate for the study. Pregnant women and women who could become pregnant were also excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiomyocyte apoptosis:the expression of key molecules in myocardial apoptosis cell signaling translation;Myocardial interstitial fibrosis:the expression of key molecules in AngII/MAPK, TGF-beta 1/MAPK, TGF-beta 1/Smad; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrocardiography;Echocardiograph; | — |
Countries
China
Contacts
Public ContactXijun Xiao
Outcome results
None listed